About Us
Taiwan Bio Therapeutics Inc. was founded in 2014, built on a cell culture technology co-developed by National Yang Ming Chiao Tung University and Taipei Veterans General Hospital to develop novel cell therapies. By integrating this technology with advanced cell engineering, we aim to enhance the accessibility of cell therapies and drive progress in regenerative medicine.
Committed to pioneering a new era in developing durable treatments for chronic and immune-related diseases
Today, Taiwan Bio Therapeutics is committed to driving innovation and accessibility in cell therapy, upholding the philosophy of “Innovating for a Healthier Future.” Through our unique FAST CGT platform, we effectively reduce costs, enhance efficacy, accelerate development processes, and shorten production cycles.
Our goal is to overcome current technological and commercial barriers, enabling long-lasting cell therapies to reach more patients and providing diverse and more effective treatment options for individuals worldwide suffering from chronic and immune-related diseases.
Our goal is to overcome current technological and commercial barriers, enabling long-lasting cell therapies to reach more patients and providing diverse and more effective treatment options for individuals worldwide suffering from chronic and immune-related diseases.
Rooted locally, expanding globally with impact
We started in Taiwan, strengthening our presence in the local market while steadily expanding our technology globally. Our mission is to drive the adoption and application of cell therapy innovations on an international scale.
Currently, Taiwan Bio Therapeutics has established strong partnerships with leading U.S. universities and research institutions to co-develop cell therapy technologies and create viable commercial models, building a comprehensive and efficient industry ecosystem. These collaborations not only enhance our R&D capabilities but also foster global exchange in cell therapy advancements, increasing the feasibility of commercial applications in the field.
Currently, Taiwan Bio Therapeutics has established strong partnerships with leading U.S. universities and research institutions to co-develop cell therapy technologies and create viable commercial models, building a comprehensive and efficient industry ecosystem. These collaborations not only enhance our R&D capabilities but also foster global exchange in cell therapy advancements, increasing the feasibility of commercial applications in the field.
Ensuring that more patients can benefit from cutting-edge cell therapies
Taiwan Bio Therapeutics, built on its innovative Therapeutics Design and Manufacturing (TDM) business model, provides comprehensive support for cell therapy products in preclinical and early clinical stages. Our services cover R&D, process optimization, clinical trials, and manufacturing, ensuring that cell therapy technologies transition rapidly and efficiently from bench to bedside.
Our goal is to ensure that more patients benefit from cutting-edge cell therapies, whether for the treatment of chronic diseases, immune-related disorders, or other severe, complex conditions, by offering innovative and practical solutions.
Our goal is to ensure that more patients benefit from cutting-edge cell therapies, whether for the treatment of chronic diseases, immune-related disorders, or other severe, complex conditions, by offering innovative and practical solutions.
Our History
2014
The company was established with the aim of promoting the widespread adoption of cell-based therapies.
2017
The product has entered clinical trials, advancing a vision of a future without chronic diseases.
2020
Launched the world's first TDM (Therapeutics Design & Manufacturing) business model for cell therapy design and production services.
2022
Acquired gene-modified mesenchymal stem cell development technology, targeting treatments for inflammatory and tissue repair-related diseases, and listed on the Emerging Stock Board.
2023
Completed the establishment of the FAST CGT platform, focusing on therapies for immune and inflammatory diseases.
2024
Became the first company in Taiwan to have an allogeneic mesenchymal stem cell product pass the TFDA PIC/S GMP pilot facility inspection.